Chimeric antigen receptor T cells (CAR-T cells) have been widely used for haematologic malignancies. Current CAR-T therapies for acute myeloid leukaemia mostly target myeloid-lineage antigens, such as CD123 and CD33, which may be associated with potential haematopoietic toxicity. As a lineage-specific receptor, CD7 is expressed in acute myeloid leukaemia cells and T cells but is not expressed in myeloid cells. The first step is again placing the cursor in the macro input field (in the vector next to the brace in this case) and pressing the wrench key in the toolbar. Therefore, the use of CD7 CAR-T cells for R/R-AML needs to be further explored. Texmacs Medium Miltenyi Using the Macro editor, let's build a new macro that places the brace on the right. In this report, immunohistochemistry and flow cytometry were used to analyse CD7 expression in clinical samples from R/R-AML patients and healthy donors (HDs). We designed naturally selected CD7 CAR-T cells to analyse various functions and in vitro antileukaemic efficacy based on flow cytometry, and xenograft models were used to validate in vivo tumour dynamics. We calculated the percentage of cells with CD7 expression in R/R-AML patients with minimal residual disease (MRD) (5/16, 31.25%) from our institution and assessed CD7 expression in myeloid and lymphoid lineage cells of R/R-AML patients, concluding that CD7 is expressed in T cells but not in myeloid cells. Subsequently, we designed and constructed naturally selected CD7 CAR-T cells (CD7 CAR). We did not perform CD7 antigen knockdown on CD7 CAR-T cells because CD7 molecule expression is naturally eliminated at Day 12 post transduction. We then evaluated the ability to target and kill CD7 + acute myeloid leukaemia cells in vitro and in vivo. Naturally selected CD7 CAR-T cells efficiently killed CD7 + acute myeloid leukaemia cells and CD7 + primary blasts of R/R-AML patients in vitro and significantly inhibited leukaemia cell growth in a xenograft mouse model. Naturally selected CD7 CAR-T cells represent an effective treatment strategy for relapsed and refractory acute myeloid leukaemia patients in preclinical studies.Īcute myeloid leukaemia (AML) is a malignancy characterized by abnormal clonal expansion of myeloid blasts in the bone marrow that impairs normal haematopoiesis, causing infection, bleeding, and anaemia. All cell processing steps are automated to ensure a highly reproducible and standardized.
The CliniMACS Prodigy Platform covers the entire workflow for the manufacture of tumor-reactive T cells: T cell stimulation, selection (by CD137 activation marker), activation, and expansion. Despite standard treatment with chemotherapeutic agents, including anthracycline and cytarabine, to achieve complete remission (CR) for patients with acute myeloid leukaemia, many patients still relapse within a short period. The five easy steps to your final tumor-reactive T cell product.
Only 35–45% of patients under the age of 60 years experience long-term remission with conventional treatment, and the proportion drops to 10–15% for those older than 60 years.
0 kommentar(er)
